Inhibitors of protein-protein interactions

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 3, 2002, Pages 393-400

  Ockey, Denise A ^a   Gadek, Thomas R ^a  

^a GENENTECH INC   (United States)

Author keywords

Antagonists; Antibodies; Bcl2; BH3 domain; Glycoprotein IIbIIIa; Grb2; HIV protease; ICAM; IL 2; Inhibitors; Integrin; LFA 1; Protein protein interaction; RGD mimetic; SH2 domain; src; Tubulin; VCAM; Vinblastine; Vinca alkaloids; Vitronectin receptor; VLA4

Indexed keywords

ABCIXIMAB; ALPHA TUBULIN; ANTIBODY; BETA TUBULIN; BETA1 INTEGRIN; CD11 ANTIGEN; CYCLOSPORIN A; DOLASTATIN; EFALIZUMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HALICHONDRIN B; INTERLEUKIN 2 RECEPTOR ANTIBODY; LOTRAFIBAN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAYTANSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; ORBOFIBAN; RHIZOXIN; ROXIFIBAN; SIBRAFIBAN; SPONGISTATIN 1; TIROFIBAN; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VITRONECTIN RECEPTOR; XEMILOFIBAN;

CANCER; CONTROLLED STUDY; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW;

EID: 0036125473     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.3.393     Document Type: Review

References (40)

1. Antagonists of protein-protein interactions
2. In vivo protein-protein interaction assays: Beyond proteins
3. New inhibitors of tubulin polymerisation
4. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle
5. Localization of the vinblastine-binding site on β-tubulin
6. Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B
7. Structure-based design of novel anticancer agents
8. New antiplatelet drugs
9. Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction
10. Interleukin-2 inhibitors in autoimmune disease
11. Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2
12. Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents
13. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain
14. NMR and mutagenesis evidence for an I-domain allosteric site that regulates lymphocyte function-associated antigen-1 ligand binding
15. Identification and characterization of antagonists of the LFA-1/ICAM-1 protein-protein interaction as novel immunomodulatory agents
16. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule
17. 3
18. Patent focus on cancer chemotherapeutics. III Angiogenesis agents: October 2000-March 2001
19. 3 integrin antagonists as inhibitors of bone resorption
20. Integrins as therapeutic targets in bone disease
21. 3 for angiogenesis
22. 3 on thrombosis and neointima after oversized porcine coronary angioplasty
23. 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy
24. Peptide and peptidomimetic inhibitors of VLA-4
25. Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents
26. α4 Integrin Antagonists
27. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS
28. Discovery of a novel binding epitope for the α4 integrin based on sequence homology between VCAM-1 and the third heavy chain complementary-determing region of anti-α4 antibodies
29. Peptidomimetic SH2 domain antagonists for targeting signal transduction
30. SH2 domain inhibition: A problem solved?
31. New inhibitors of SH2-mediated processes
32. SH2 and SH3 domains: Potential targets for anti-cancer drug design
33. Emerging therapeutic targets in caspase-dependent disease
34. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-XL
35. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases
36. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
37. Inhibiting the assembly of protein-protein interfaces
38. Small-molecule inhibitors of HIV-1 protease dimerization derived from cross-linked interfacial peptides
39. Inhibition of HIV-1 Protease by a Subunit of Didemnaketal A